Vistagen plans FDA meeting on fasedienol path after mixed PALISADE-4 data

Vistagen reported financial results for its fiscal year 2027 first quarter ended June 30, 2026, on August 14, 2026, and said FDA engagement is planned during the current quarter regarding a potential future Phase 3 path forward for fasedienol in social anxiety disorder.¹

In the PALISADE-4 Phase 3 study, although fasedienol did not achieve its primary endpoint in the overall trial population, a post-hoc analysis of a subpopulation of patients with very severe social anxiety showed nominally statistically significant improvement compared to placebo.¹ Safety and tolerability data were described as consistent with previous placebo-controlled trials.¹

The company also reported preliminary data from the open-label extension of PALISADE-3. Fasedienol taken as needed for up to 12 months was observed to be well-tolerated with no new drug-related safety findings, and preliminary exploratory efficacy data over the first four months showed improvement over time on the Liebowitz Social Anxiety Scale and the Social Phobia Inventory,¹ though these observations were uncontrolled and open-label and should be interpreted with caution.¹

In an exploratory Phase 2 repeat dose study of two 3.2 µg doses given ten minutes apart versus a single dose and placebo, the study did not demonstrate statistically significant differences overall, but both active arms showed numerical separation from placebo, with nominally significant responses in the very severe social anxiety subgroup for the single-dose arm and pooled analysis.¹

On regulatory matters, Vistagen said it received the FDA's "Study May Proceed" letter for refisolone under its open IND for moderate-to-severe vasomotor symptoms due to menopause.¹

R&D expense was $10.9 million versus $11.7 million a year earlier, and R&D expenses are expected to keep decreasing following the conclusion of PALISADE-4 and the repeat dose study, though future trends depend on FDA feedback on a registrational pathway.¹ Cash, cash equivalents, and marketable securities were $31.7 million as of June 30, 2026, and the company believes this is sufficient to fund operations into 2027 but not enough to extend its runway beyond a year from now.¹